Olema Pharmaceuticals, Inc. (OLMA) Stock Score, Valuation & Financial Research

Olema Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for OLMA

Olema Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 7.45. These figures are a research snapshot, not a buy or sell recommendation.

What Olema Pharmaceuticals, Inc. does

Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and strategic collaborations to fund the research, development, and clinical testing of its proprietary oncology product candidates.

Products and services

  • The company is developing palazestrant, a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) for the treatment of ER+/HER2- breast cancer.

Brands and product families

  • Palazestrant — Lead product candidate in clinical development for ER+/HER2- breast cancer. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of its product candidates for non-clinical and clinical testing. Source

Business relationships and partnerships

  • Pfizer — Clinical trial agreement to evaluate palazestrant in combination with atirmociclib in patients with ER+/HER2- metastatic breast cancer. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing endocrine therapies and other treatments for breast cancer, including those with approved products or candidates in clinical development. Source

Business strengths to evaluate

  • Proprietary CERAN/SERD platform technology Source

Business risks and research considerations

  • Dependence on third-party manufacturers Source
  • History of operating losses and lack of product revenue Source

Sources: Company research source · Pfizer

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

OLMA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.45
Market capitalization:
650.74M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -204.57M
Free cash flow:
USD -146.72M
Cash:
USD 48.6M
Total debt:
USD 660K
EPS:
USD -2.12

What stands out

  • Free cash flow is USD -146.72M, negative for the stored period.
  • The balance sheet shows USD 48.6M of cash versus USD 660K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 47.94M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for OLMA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can OLMA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is OLMA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for OLMA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of OLMA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-12.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research OLMA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.